<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31601" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperbaric Treatment of Central Retinal Artery Occlusion</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hendriksen</surname>
            <given-names>Stephen</given-names>
          </name>
          <aff>Hennepin County Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cooper</surname>
            <given-names>Jeffrey S.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Hendriksen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeffrey Cooper declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31601.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Central retinal artery occlusion (CRAO) is a relatively rare but potentially devastating ocular emergency. Patients present with sudden, painless monocular vision loss. The prognosis for visual recovery is poor, and until recently, no treatment could restore any degree of functional vision to the affected eye. Central retinal artery occlusion leads to retinal hypoxia, and the retinal tissue is incredibly intolerant of hypoxia. In 2006, hyperbaric oxygen therapy was approved for treating central retinal artery occlusion. However, it remains a vastly underutilized modality, partially due to insufficient availability and awareness in the ophthalmology community. This activity describes the pathophysiology, evaluation, and management of central retinal artery occlusion and highlights the role of the interprofessional team in caring for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of central retinal artery occlusion.</p></list-item><list-item><p>Differentiate the presentation of a patient with central retinal artery occlusion.</p></list-item><list-item><p>Determine the treatment and management options available for central retinal artery occlusion.</p></list-item><list-item><p>Summarize a well-coordinated interprofessional team approach to care for patients affected by central retinal artery occlusion effectively.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31601&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31601">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31601.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Central retinal&#x000a0;artery occlusion&#x000a0;(CRAO) is a relatively rare emergency and potentially devastating eye condition. Patients present with sudden, painless monocular vision loss. The prognosis for visual recovery is poor, and up until recently, no treatment could be offered to restore at least some functional vision to the affected eye. The retina has the highest oxygen consumption rate of any organ in the body at 13 mL/100 gm per minute. Retinal tissue is not tolerant of hypoxia. Until 2006, when hyperbaric oxygen therapy was approved for central retinal artery occlusion treatment, ophthalmologists had no treatment options for these patients. It is still a vastly underutilized modality, partially due to a lack of availability and knowledge in the ophthalmology community.<xref ref-type="bibr" rid="article-31601.r1">[1]</xref><xref ref-type="bibr" rid="article-31601.r2">[2]</xref><xref ref-type="bibr" rid="article-31601.r3">[3]</xref><xref ref-type="bibr" rid="article-31601.r4">[4]</xref></p>
      </sec>
      <sec id="article-31601.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Patients at increased risk for developing&#x000a0;central retinal&#x000a0;artery occlusion&#x000a0;are those with:</p>
        <list list-type="bullet">
          <list-item>
            <p>Giant cell arteritis</p>
          </list-item>
          <list-item>
            <p>Atherosclerosis</p>
          </list-item>
          <list-item>
            <p>Thromboembolic disease</p>
          </list-item>
          <list-item>
            <p>Vasospasm<xref ref-type="bibr" rid="article-31601.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>Arterial supply to the eye is&#x000a0;via the&#x000a0;ophthalmic artery, a branch of the cavernous portion of the internal carotid artery. The central retinal artery enters the globe along with the optic nerve and serves the inner layers of the retina through its many branches. Fifteen percent to 30% of the population have a cilioretinal artery, part of the choroidal arterial supply. This supplies the area of the retina around the macula, which is the central vision area. Patients with a cilioretinal artery may still have preserved central vision because this portion of the retina is still being perfused.</p>
        <p>In central retinal&#x000a0;artery occlusion, the inner retinal layers normally served by the retinal circulation will die. This is what causes the vision loss. However, these layers may receive enough oxygen via diffusion from the choroidal circulation to maintain viability if the patient is exposed to increased FiO2. Normally, the choroidal circulation supplies most of the oxygen to the retina.<xref ref-type="bibr" rid="article-31601.r6">[6]</xref><xref ref-type="bibr" rid="article-31601.r7">[7]</xref><xref ref-type="bibr" rid="article-31601.r8">[8]</xref></p>
      </sec>
      <sec id="article-31601.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>CRAO tends to occur more often in men. It occurs in about 1 out of 50,000-100,000&#x000a0;with a&#x000a0;mean age of 60-65.<xref ref-type="bibr" rid="article-31601.r9">[9]</xref></p>
        <p>CRAO due to arteritis is most commonly caused by giant cell arteritis, but systemic lupus er&#x000ad;ythematosus, polyarteritis nodosa, and other vasculitides can also lead to CRAO. However, most&#x000a0;CRAOs are nonarteritic. In fact, 90% are nonarteritic. Carotid artery disease is the most common cause of retinal artery occlusion, accounting for about 70% of cases.<xref ref-type="bibr" rid="article-31601.r10">[10]</xref>&#x000a0;Other non-inflammatory causes include emboli (e.g., atrial fibrillation), hypercoagulable disorders,&#x000a0;hematological cancers, and sickle cell anemia.</p>
        <p>Central retinal artery occlusion is a rare, emergent eye condition that should be suspected in any patient with unilateral, sudden, painless vision loss. These patients usually present with vision loss limited to finger counting or&#x000a0;light perception. If there is no light perception, the ophthalmic artery may be occluded, which causes permanent and debilitating vision loss that would not be amenable to HBO2 treatment as this would preclude any ciliary collateral circulation, which could maintain retinal viability with HBO2. However, it may be addressed by thrombolysis.</p>
      </sec>
      <sec id="article-31601.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>If the level of occlusion is at the ophthalmic artery, there may be no treatment options available to the patient. This is because posterior ciliary circulation is blocked, and there is no collateral circulation to the inner layers of the retina.<xref ref-type="bibr" rid="article-31601.r11">[11]</xref><xref ref-type="bibr" rid="article-31601.r12">[12]</xref><xref ref-type="bibr" rid="article-31601.r13">[13]</xref></p>
        <p>Therapy must be started before the tissue is irreparably damaged.</p>
        <p>The degree and location of occlusion will affect the response to treatment.</p>
        <p>The adequate partial pressure of oxygen must be maintained long enough for the retinal vessels to recanalize. This usually occurs within 72 hours.</p>
        <p>The most extensive published case series (Hayreh) showed the natural progression of disease without treatment with hyperbaric oxygen.<xref ref-type="bibr" rid="article-31601.r14">[14]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Some patients had transient symptoms for minutes to hours that resolved without treatment, and they&#x000a0;were left with minimal visual impairment.</p>
          </list-item>
          <list-item>
            <p>Some patients have a variant retinal vascular supply, the&#x000a0;cilioretinal artery. This occurs in almost half the population and about one-third of all eyes. There is much variability in how much of the retina is supplied by such arteries.<xref ref-type="bibr" rid="article-31601.r15">[15]</xref>&#x000a0;These arteries can aid in sparing some of the central retinal function.</p>
          </list-item>
          <list-item>
            <p>Without HBO2 therapy, the natural outcomes for patients without cilioretinal arteries are poor, with less than 2% ending up with recovery of baseline vision and most (80%) ending up with light perception, motion detection, or finger counting at best.<xref ref-type="bibr" rid="article-31601.r14">[14]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients with cilioretinal arteries had much better outcomes.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31601.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>CRAO presents as sudden onset, painless loss of vision. Usually, there is only light perception, hand motion detection, or finger counting, and visual acuity is often worse than 20/200.</p>
        <p>A patient's lack of light perception may indicate an ophthalmic artery occlusion; therefore, no blood flows to choroidal vessels.</p>
        <p>If central visual acuity is spared and fundoscopy is consistent with&#x000a0;central retinal&#x000a0;artery occlusion, the patient probably has a cilioretinal artery blood supply. The fundoscopy may show a pale yellow ischemic retina. A cherry-red spot may be present where the macula is, but this is not a consistent or reliable finding. The cherry red spot is&#x000a0;associated with poor outcomes.<xref ref-type="bibr" rid="article-31601.r16">[16]</xref></p>
      </sec>
      <sec id="article-31601.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>This is a "stroke of the eye" and should be treated with the same urgency as an evolving stroke or myocardial infarction. Oxygen by non-rebreather mask should be initiated immediately while performing the evaluation. Fundoscopy should be performed and documented immediately. An ophthalmologist should be consulted, preferably a vitreoretinal specialist. The presence of pain, a history of trauma, findings of flashers or floaters, and age younger than 40 years are more common with ocular trauma, retinal detachment, or vitreal hemorrhage and make central retinal&#x000a0;artery occlusion&#x000a0;less likely.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-31601.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>General Treatment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Provide immediate supplemental oxygen at the highest normobaric FiO2 available.</p>
          </list-item>
          <list-item>
            <p>Consult ophthalmology, but do not delay treatment if readily available.</p>
          </list-item>
          <list-item>
            <p>Baseline complete blood count (CBC), ESR, C-reactive protein&#x000a0;(CRP), prothrombin time (PT), partial thromboplastin time (PTT), INR if on coumadin</p>
          </list-item>
          <list-item>
            <p>ECG</p>
          </list-item>
          <list-item>
            <p>Carotid ultrasound, MRI, and echocardiogram can be done later. These are not urgent studies for these patients but are part of the complete assessment for risk factor modification, just as in stroke.</p>
          </list-item>
          <list-item>
            <p>If the onset of symptoms is within 24 hours of presentation, and the patient has no response to normobaric hyperoxia after 15 minutes, refer for emergency hyperbaric medicine consultation.<xref ref-type="bibr" rid="article-31601.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hyperbaric Oxygen Treatment Protocol<xref ref-type="bibr" rid="article-31601.r18">[18]</xref></bold>
</p>
        <p>Indicated for central retinal&#x000a0;artery occlusion<bold>&#x000a0;</bold></p>
        <p>Initial treatment:</p>
        <list list-type="bullet">
          <list-item>
            <p>Compress to 2 atmosphere absolute (ATA).</p>
          </list-item>
          <list-item>
            <p>If vision improves significantly at 2 ATA, remain at this depth for 90 minutes.</p>
          </list-item>
          <list-item>
            <p>If vision fails to improve after 30 minutes at&#x000a0;2 ATA, then compress to 2.4&#x000a0;ATA; if vision improves at this depth, treat at this depth for 90 minutes. If there is no improvement at 2.4 ATA, compress to 2.8 ATA and perform the US&#x000a0;Navy Treatment Table No. 6.</p>
          </list-item>
        </list>
        <p>If there is&#x000a0;<italic toggle="yes">no improvement</italic> after the initial US Navy Table No. 6, options are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Discontinue treatment</p>
          </list-item>
          <list-item>
            <p>Continue with normobaric oxygen therapy</p>
          </list-item>
          <list-item>
            <p>Give two additional treatments at 2.8 ATA for 90 minutes with 5-minute air breaks every 30 minutes 2 times per day, and reassess after 4 to 6 days. Most patients will reach a plateau, after which they will not experience any further improvement in visual acuity, and treatment can then be discontinued. Some patients require eight treatments before improving visual acuity, but few, if any, patients will respond beyond this point.</p>
          </list-item>
        </list>
        <p>A more straightforward protocol with good results treats at 2.5 ATA for 90 minutes with 5-minute air breaks every 30 minutes 2 times daily for 2-3 weeks.<xref ref-type="bibr" rid="article-31601.r19">[19]</xref>&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Fluorescein angiography can be a safe and valuable tool to evaluate these patients for successful recanalization of the central retinal artery.<xref ref-type="bibr" rid="article-31601.r20">[20]</xref></p>
      </sec>
      <sec id="article-31601.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential for acute painless vision loss includes central retinal vein occlusion, vitreous hemorrhage, retinal detachment, posterior circulation stroke, ischemic optic neuropathy, and amaurosis fugax.</p>
      </sec>
      <sec id="article-31601.s10" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>An unfavorable meta-analysis was published in 2002, which failed to show a significant improvement in CRAO outcomes with HBO2 despite most of them being treated within 12 hours of symptom onset.<xref ref-type="bibr" rid="article-31601.r21">[21]</xref>&#x000a0;Another equivocal study compared outcomes between two hospitals, one of which used HBO2 and the other which did not. Although outcomes were better with HBO2, the clinical significance was minimal, and no significant difference was seen for those achieving visual acuity better than 20/200.<xref ref-type="bibr" rid="article-31601.r22">[22]</xref></p>
        <p>There is an exploration of hyperbaric oxygen for central retinal vein occlusions,&#x000a0;as there is little literature support beyond case reports and small series. However, case reports of good resolution despite delays in treatment in CRVO patients are encouraging.<xref ref-type="bibr" rid="article-31601.r23">[23]</xref></p>
        <p>Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients.ClinicalTrials.gov ID NCT02405741Sponsor Assaf-Harofeh Medical Center</p>
      </sec>
      <sec id="article-31601.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients treated with hyperbaric oxygen within 8 hours of symptom onset have an 83% chance of improving visual acuity of 3 lines or better on the Snellen chart.<xref ref-type="bibr" rid="article-31601.r24">[24]</xref>&#x000a0;A report on 39 patients with CRAO noted a 72% improvement with an average of 5 lines of improvement on a modified Snellen chart.<xref ref-type="bibr" rid="article-31601.r22">[22]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-31601.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Neovascularization after CRAO can occur, particularly in people with diabetes.&#x000a0; This can lead to long-term visual loss, neovascular glaucoma, and vitreous hemorrhage, even in the face of initial salvage of vision with HBO2.<xref ref-type="bibr" rid="article-31601.r25">[25]</xref><xref ref-type="bibr" rid="article-31601.r12">[12]</xref>&#x000a0;It is unknown whether&#x000a0;treatment with HBO2 affects this process.<xref ref-type="bibr" rid="article-31601.r25">[25]</xref></p>
        <p>HBO2 is usually well tolerated, although some will have issues with confinement anxiety and otic barotrauma.&#x000a0; Other complications are rare.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-31601.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Immediate presentation to healthcare is a must, as CRAO is a very time-sensitive disease.&#x000a0; Visual salvage is dependent on rapid initiation of HBO2 and potentially thrombolytics.&#x000a0; Patients at risk should be advised to present directly to an emergency department should they develop sudden visual loss.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-31601.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Recovery or improvement of visual acuity during the initial treatment of central retinal&#x000a0;artery occlusion&#x000a0;with Hyperbaric Oxygen (HBO2) indicates retinal viability and the potential for return of vision despite the ischemic period suffered before treatment.</p>
        <p>A primate study demonstrated no retinal damage if retinal&#x000a0;ischemia was stopped&#x000a0;within 90 minutes. Damage ensued shortly after that, with 240 min&#x000ad;utes producing irreversible damage.<xref ref-type="bibr" rid="article-31601.r26">[26]</xref></p>
        <p>Animal models have shown reduced cell loss from 58% to 30% in animals treated with HBO2 after experimental&#x000a0;central retinal&#x000a0;artery occlusion.<xref ref-type="bibr" rid="article-31601.r27">[27]</xref></p>
        <p>Acute central retinal artery obstruction, even when treated promptly, often results in severe, permanent vision loss.<xref ref-type="bibr" rid="article-31601.r2">[2]</xref></p>
        <p>Recent studies are looking at using thrombolytics and surgical removal of clots, and while this is promising, outcomes have been disappointing.<xref ref-type="bibr" rid="article-31601.r28">[28]</xref><xref ref-type="bibr" rid="article-31601.r29">[29]</xref><xref ref-type="bibr" rid="article-31601.r30">[30]</xref></p>
        <p>Supplemental O2 is a mainstay in the treatment of central retinal&#x000a0;artery occlusion. Retinal blood flow may be reestablished in 72 hours via recanalization. However, if ischemia and hypoxia have resulted in cell death and necrosis of the inner retinal layers usually supplied by the retinal artery, vision may not return with recanalization. The ischemic penumbra is tissue capable of recovery within a specific timeframe.<xref ref-type="bibr" rid="article-31601.r17">[17]</xref></p>
        <p>Central retinal artery occlusion should be treated as a stroke of the eye and admitted to the hospital for close monitoring, testing, and risk factor modification.<xref ref-type="bibr" rid="article-31601.r31">[31]</xref></p>
        <p>Hyperbaric oxygen for central retinal&#x000a0;artery occlusion&#x000a0;is a level IIB recommendation of the Undersea and Hyperbaric Medical Society (American Heart Association classification).<xref ref-type="bibr" rid="article-31601.r32">[32]</xref> It is one of the only treatments we can offer to patients who suffer from this debilitating condition.</p>
      </sec>
      <sec id="article-31601.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>CRAO is best managed by an interprofessional team that includes ER triage nurses. Clinicians need to know that CRAO is a medical emergency. There were no treatments for this condition in the past, but now numerous series indicate that HBO therapy may help. Thus, triage and rapid transfer of these patients to an HBO chamber is paramount if vision is to be saved. Fundoscopy should be performed and documented immediately. An ophthalmologist should be consulted, preferably a vitreoretinal specialist. Ideally, patients with CRAO are evaluated by a stroke team (neurology).&#x000a0;&#x000a0;</p>
        <p>Patients with CRAO with symptom duration of less than 6 to 8 hours have the best outcomes after HBO therapy.<xref ref-type="bibr" rid="article-31601.r4">[4]</xref><xref ref-type="bibr" rid="article-31601.r33">[33]</xref><xref ref-type="bibr" rid="article-31601.r4">[4]</xref></p>
      </sec>
      <sec id="article-31601.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31601&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31601">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/hyperbaric-treatment-of-central-retinal-artery-occlusion/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31601">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31601/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31601">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-31601.s17">
        <fig id="article-31601.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Central Retinal Artery Occlusions.&#x000a0;Fundoscopic exam findings in central retinal artery occlusions, including a cherry red fovea, optic disk pallor, and boxcar segmentation of the retinal veins. Contributed by Evan J Kaufman, OD, FAAO. University of Virginia, Department of Ophthalmology.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CRAO" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-31601.s18">
        <title>References</title>
        <ref id="article-31601.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guler Alis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Acikalin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ucal</surname>
                <given-names>YO</given-names>
              </name>
            </person-group>
            <article-title>Transient Retinal Artery Occlusion After Uncomplicated Rhinoplasty.</article-title>
            <source>J Craniofac Surg</source>
            <year>2019</year>
            <season>May/Jun</season>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>e221</fpage>
            <page-range>e221-e224</page-range>
            <pub-id pub-id-type="pmid">30730513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>IN</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of central retinal artery occlusion using hyperbaric oxygen therapy.</article-title>
            <source>Clin Exp Emerg Med</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>278</fpage>
            <page-range>278-281</page-range>
            <pub-id pub-id-type="pmid">30571907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bagli</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>&#x000c7;evik</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>&#x000c7;evik</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Effect of hyperbaric oxygen treatment in central retinal artery occlusion.</article-title>
            <source>Undersea Hyperb Med</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>421</fpage>
            <page-range>421-425</page-range>
            <pub-id pub-id-type="pmid">30241121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Oxygen therapy in patients with retinal artery occlusion: A meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>e0202154</fpage>
            <pub-id pub-id-type="pmid">30157206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naravane</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Abel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Retinal Vasospasm-Induced Central Retinal Artery Occlusion and the Possible Role for Hyperbaric Oxygen Treatment.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2023</year>
            <month>Nov</month>
            <day>06</day>
            <pub-id pub-id-type="pmid">37938116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butler</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Hagan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Van Hoesen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murphy-Lavoie</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Management of central retinal artery occlusion following successful hyperbaric oxygen therapy: case report.</article-title>
            <source>Undersea Hyperb Med</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-107</page-range>
            <pub-id pub-id-type="pmid">29571239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elder</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rawstron</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric oxygen in the treatment of acute retinal artery occlusion.</article-title>
            <source>Diving Hyperb Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>233</fpage>
            <page-range>233-238</page-range>
            <pub-id pub-id-type="pmid">29241233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Youn</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Lavin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Patrylo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schindler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kirshner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Schrag</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Current treatment of central retinal artery occlusion: a national survey.</article-title>
            <source>J Neurol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>265</volume>
            <issue>2</issue>
            <fpage>330</fpage>
            <page-range>330-335</page-range>
            <pub-id pub-id-type="pmid">29236169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rumelt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dorenboim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rehany</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Aggressive systematic treatment for central retinal artery occlusion.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>128</volume>
            <issue>6</issue>
            <fpage>733</fpage>
            <page-range>733-8</page-range>
            <pub-id pub-id-type="pmid">10612510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babikian</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wijman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Koleini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Matjucha</surname>
                <given-names>IC</given-names>
              </name>
            </person-group>
            <article-title>Retinal ischemia and embolism. Etiologies and outcomes based on a prospective study.</article-title>
            <source>Cerebrovasc Dis</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>108</fpage>
            <page-range>108-13</page-range>
            <pub-id pub-id-type="pmid">11490104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soares</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Mendon&#x000e7;a</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of hyperbaric oxygen therapy in the treatment of central retinal artery occlusion.</article-title>
            <source>BMJ Case Rep</source>
            <year>2017</year>
            <month>May</month>
            <day>12</day>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">28500127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Parke</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Early Onset of Ocular Neovascularization After Hyperbaric Oxygen Therapy in a Patient With Central Retinal Artery Occlusion.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>263</fpage>
            <page-range>263-269</page-range>
            <pub-id pub-id-type="pmid">27613631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olson</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Lentz</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Central Retinal Artery Occlusion: A Literature Review and the Rationale for Hyperbaric Oxygen Therapy.</article-title>
            <source>Mo Med</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>113</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-7</page-range>
            <pub-id pub-id-type="pmid">27039492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayreh</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Central retinal artery occlusion: visual outcome.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>140</volume>
            <issue>3</issue>
            <fpage>376</fpage>
            <page-range>376-91</page-range>
            <pub-id pub-id-type="pmid">16138997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Justice</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Cilioretinal arteries. A study based on review of stereo fundus photographs and fluorescein angiographic findings.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1976</year>
            <month>Aug</month>
            <volume>94</volume>
            <issue>8</issue>
            <fpage>1355</fpage>
            <page-range>1355-8</page-range>
            <pub-id pub-id-type="pmid">949278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadanny</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maliar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fishlev</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bechor</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bergan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Avni</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Efrati</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reversibility of retinal ischemia due to central retinal artery occlusion by hyperbaric oxygen.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>115</fpage>
            <page-range>115-125</page-range>
            <pub-id pub-id-type="pmid">28096655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Celebi</surname>
                <given-names>ARC</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric Oxygen Therapy for Central Retinal Artery Occlusion: Patient Selection and Perspectives.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2021</year>
            <volume>15</volume>
            <fpage>3443</fpage>
            <page-range>3443-3457</page-range>
            <pub-id pub-id-type="pmid">34413628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy-Lavoie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Hagan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Arterial insufficiencies: Central retinal artery occlusion.</article-title>
            <source>Undersea Hyperb Med</source>
            <year>2022</year>
            <season>Fourth Quarter</season>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>533</fpage>
            <page-range>533-547</page-range>
            <pub-id pub-id-type="pmid">36446298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Vincenzo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kauert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martiano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chiabo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Di Vincenzo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sozonoff</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baillif</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of a standardized hyperbaric oxygen therapy protocol for retinal artery occlusion.</article-title>
            <source>Undersea Hyperb Med</source>
            <year>2022</year>
            <season>Fourth Quarter</season>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>495</fpage>
            <page-range>495-505</page-range>
            <pub-id pub-id-type="pmid">36446295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiabo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kauert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casolla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Contenti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nahon-Esteve</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baillif</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arnaud</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of hyperbaric oxygen therapy monitored by fluorescein angiography in patients with retinal artery occlusion.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2024</year>
            <month>Jun</month>
            <day>20</day>
            <volume>108</volume>
            <issue>7</issue>
            <fpage>956</fpage>
            <page-range>956-962</page-range>
            <pub-id pub-id-type="pmid">37722767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosignoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bahadorani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Effects of Hyperbaric Oxygen Therapy in Patients with Central Retinal Artery Occlusion: A Retrospective Study, Systematic Review, and Meta-analysis.</article-title>
            <source>Korean J Ophthalmol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>108</fpage>
            <page-range>108-113</page-range>
            <pub-id pub-id-type="pmid">34743490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masters</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Westgard</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Hendriksen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Decanini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Logue</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Linduska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>CASE SERIES OF HYPERBARIC OXYGEN THERAPY FOR CENTRAL RETINAL ARTERY OCCLUSION.</article-title>
            <source>Retin Cases Brief Rep</source>
            <year>2021</year>
            <month>Nov</month>
            <day>01</day>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>783</fpage>
            <page-range>783-788</page-range>
            <pub-id pub-id-type="pmid">31306292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Retinal Artery and Vein Occlusions Successfully Treated with Hyperbaric Oxygen.</article-title>
            <source>Clin Pract Cases Emerg Med</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>338</fpage>
            <page-range>338-340</page-range>
            <pub-id pub-id-type="pmid">31763582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beiran</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goldenberg</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Adir</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tamir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shupak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Early hyperbaric oxygen therapy for retinal artery occlusion.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2001</year>
            <season>Oct-Dec</season>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>345</fpage>
            <page-range>345-50</page-range>
            <pub-id pub-id-type="pmid">11820305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>John Blegen</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Wedel</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Outcomes After Central Retinal Artery Occlusion Treated Acutely With Hyperbaric Oxygen Therapy: A Case Series.</article-title>
            <source>J Vitreoretin Dis</source>
            <year>2021</year>
            <season>Mar-Apr</season>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>142</fpage>
            <page-range>142-146</page-range>
            <pub-id pub-id-type="pmid">37009086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayreh</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kolder</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Weingeist</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Central retinal artery occlusion and retinal tolerance time.</article-title>
            <source>Ophthalmology</source>
            <year>1980</year>
            <month>Jan</month>
            <volume>87</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-8</page-range>
            <pub-id pub-id-type="pmid">6769079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaydar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ezrachi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dratviman-Storobinsky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hofstetter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Avraham-Lubin</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Goldenberg-Cohen</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Reduction of apoptosis in ischemic retinas of two mouse models using hyperbaric oxygen treatment.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2011</year>
            <month>Sep</month>
            <day>29</day>
            <volume>52</volume>
            <issue>10</issue>
            <fpage>7514</fpage>
            <page-range>7514-22</page-range>
            <pub-id pub-id-type="pmid">21873680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raber</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Gmeiner</surname>
                <given-names>FV</given-names>
              </name>
              <name>
                <surname>Dreyhaupt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ludolph</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Kassubek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Althaus</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Thrombolysis in central retinal artery occlusion: a retrospective observational study.</article-title>
            <source>J Neurol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>270</volume>
            <issue>2</issue>
            <fpage>891</fpage>
            <page-range>891-897</page-range>
            <pub-id pub-id-type="pmid">36305969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreira</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tavares-Ferreira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ara&#x000fa;jo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Acute phase treatment in central retinal artery occlusion: thrombolysis, hyperbaric oxygen therapy or both?</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>984</fpage>
            <page-range>984-988</page-range>
            <pub-id pub-id-type="pmid">32166539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Intravenous thrombolysis in patients with central retinal artery occlusion: a systematic review and meta-analysis.</article-title>
            <source>J Neurol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>269</volume>
            <issue>4</issue>
            <fpage>1825</fpage>
            <page-range>1825-1833</page-range>
            <pub-id pub-id-type="pmid">34625849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Tschoe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coffman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kittel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Vu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Fargen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>SQ</given-names>
              </name>
            </person-group>
            <article-title>Management of Acute Central Retinal Artery Occlusion, a "Retinal Stroke": An Institutional Series and Literature Review.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>105531</fpage>
            <pub-id pub-id-type="pmid">33310593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy-Lavoie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hagan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Central retinal artery occlusion treated with oxygen: a literature review and treatment algorithm.</article-title>
            <source>Undersea Hyperb Med</source>
            <year>2012</year>
            <season>Sep-Oct</season>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>943</fpage>
            <page-range>943-53</page-range>
            <pub-id pub-id-type="pmid">23045923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31601.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St Peter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sethuraman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric oxygen therapy for central retinal artery occlusion: Visual acuity and time to treatment.</article-title>
            <source>Undersea Hyperb Med</source>
            <year>2023</year>
            <season>Third Quarter</season>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-264</page-range>
            <pub-id pub-id-type="pmid">37708058</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
